Company intelligence / Profile preview
Jalon Therapeutics
Paris, Île-de-France (Paris), Francejalontx.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead candidate JRT39 has shown superior preclinical efficacy, stability, and pharmacokinetic profiles. The company’s peptides block critical protein interactions inside cancer cells and induce membranolysis in tumor cells. Preclinical data suggest potential for broad anti-cancer activity with a novel mechanism of action. Clinical results are not yet available as the programs are preclinical.
- Therapeutic areas
- Oncology
- Modalities
- Peptides (molecular decoys)Targeted protein-protein interaction inhibitors
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Bpifrance (funding/investment partnership)
Beyond the preview
Go deeper on Jalon Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jalon Therapeutics.